anti-steap2/exatecan antibody-drug conjugate azd0516
Generic: Anti-STEAP2/Exatecan Antibody-drug Conjugate AZD0516
anti-steap2/exatecan antibody-drug conjugate azd0516: 1 clinical trial tracked.
anti-steap2/exatecan antibody-drug conjugate azd0516 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-steap2/exatecan antibody-drug conjugate azd0516, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trials (1)
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Metastatic Prostate Cancer
Primary endpoint: Module 1 and 2: Parts A and B: Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interests (AESIs)
InterventionalRandomizedopen177 targetStarted 2025-10Completion 2029-0150 sites · Brazil, China, France, Italy…AstraZeneca